Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07627191 · ClinicalTrials.gov registry record · Early Phase 1
GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer
A Early Phase 1 study, sponsored by University of Arizona.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
NCT07627191 is a Early Phase 1 study that has not yet begun recruiting, run by University of Arizona. The registered enrollment target is 30 participants.
The verdict
NCT07627191, a Early Phase 1 study, has not yet begun recruiting, sponsored by University of Arizona.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
There is a growing number of patients diagnosed with gastrointestinal cancers who are also simultaneously being treated with GLP-1 Receptor Agonists (RA)s. To date, no clinical trial data exists to establish safety and/or feasibility with use of GLP-1 RAs during chemotherapy in the metastatic setting. The goal of this clinical trial is to evaluate the safety, tolerability, preliminary efficacy, and correlative analyses of combining GLP-1 RAs with standard chemotherapy in patients with metastatic pancreatic, colorectal, or hepatocellular cancers in the first-line setting.
Interventions
- DRUG GLP1-RA (semaglutide)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-07-10 |
| Est. Completion | 2028-06-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07627191
The ClinicalTrials.gov registry entry for NCT07627191 describes a study currently listed as not yet recruiting, categorized as Early Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GLP1-RA (semaglutide) is the first listed.
NCT07627191 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07627191 about?
NCT07627191 is a clinical study titled "GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer". There is a growing number of patients diagnosed with gastrointestinal cancers who are also simultaneously being treated with GLP-1 Receptor Agonists (RA)s. To date, no clinical trial data exists to establish safety and/or feasibility with use of GLP-1 RAs during chemotherapy in the metastatic settin...
What is the current status of trial NCT07627191?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2026-07-10. Estimated completion is 2028-06-30.
What interventions are being tested in trial NCT07627191?
The interventions under investigation include: GLP1-RA (semaglutide) (DRUG).
Who is sponsoring clinical trial NCT07627191?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.